Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Added 49 days ago (16.10.2021)
Authors: Alison J Moskowitz; Paola Ghione; Eric D Jacobsen; Jia Ruan; Jonathan H Schatz; Sarah J Noor; Patricia L Myskowski; Santosha A Vardhana; Nivetha Ganesan; Helen Hancock; Theresa Davey; Leslie Perez; Sunyoung Ryu; Alayna Marie Santarosa; Jack Dowd; Obadi Obadi; Lauren Danielle Pomerantz; Nancy Yi; Samia Sohail; Natasha Galasso; Rachel Neuman; Brielle Liotta; William Blouin; Jeeyeon Baik; Mark Blaine Geyer; Ariela Noy; David J Straus; Priyadarshini Kumar; Ahmet Dogan; Travis J Hollmann; Esther Drill; Jürgen Rademaker; Heiko Schöder; Giorgio Ga Inghirami; David M Weinstock; Steven M Horwitz
Journal: Blood
Read article